Evaluation of Ac-Lys
800CW-TATE
Intra-operative guidance
Meningioma
Molecular fluorescence guided surgery
Somatostatin receptor subtype 2
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
26
01
2021
accepted:
12
03
2021
pubmed:
27
3
2021
medline:
15
12
2021
entrez:
26
3
2021
Statut:
ppublish
Résumé
Meningioma recurrence rates can be reduced by optimizing surgical resection with the use of intraoperative molecular fluorescence guided surgery (MFGS). We evaluated the potential of the fluorescent tracer 800CW-TATE for MFGS using in vitro and in vivo models. It targets somatostatin receptor subtype 2 (SSTR Binding affinity of 800CW-TATE was evaluated using [ 800CW-TATE binding affinity assays showed an IC 800CW-TATE demonstrated sufficient binding affinity, specific SSTR
Identifiants
pubmed: 33768405
doi: 10.1007/s11060-021-03739-1
pii: 10.1007/s11060-021-03739-1
pmc: PMC8211583
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
211-222Commentaires et corrections
Type : ErratumIn
Références
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290
pubmed: 28404198
J Neurosurg. 1995 May;82(5):864-73
pubmed: 7714613
J Nucl Med. 2017 Oct;58(10):1609-1614
pubmed: 28450563
Am J Clin Oncol. 2009 Feb;32(1):73-85
pubmed: 19194129
Nat Commun. 2018 Sep 18;9(1):3739
pubmed: 30228269
J Surg Res. 2019 Oct;242:145-150
pubmed: 31077946
Acta Neuropathol. 2015 Sep;130(3):441-3
pubmed: 26195322
Lancet. 2004 May 8;363(9420):1535-43
pubmed: 15135603
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
J Nucl Med. 2015 Feb;56(2):171-6
pubmed: 25593116
J Nucl Med. 2021 Mar;62(3):342-347
pubmed: 32680922
Ann Surg Oncol. 2012 Nov;19(12):3879-87
pubmed: 22669455
Gut. 2019 Jan;68(1):7-10
pubmed: 29247063
Mol Imaging Biol. 2013 Dec;15(6):722-9
pubmed: 23715932
Eur J Pharm Biopharm. 2016 Jul;104:226-34
pubmed: 27179587
J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
pubmed: 13406590
Acta Neurochir (Wien). 2018 Aug;160(8):1539-1546
pubmed: 29858948
Neuro Oncol. 2015 Feb;17(2):312-9
pubmed: 25008094
Neurosurg Focus. 2007;23(4):E12
pubmed: 17961036
Eur J Nucl Med. 2000 Mar;27(3):273-82
pubmed: 10774879
J Neuroimaging. 2019 Sep;29(5):650-656
pubmed: 31107591
Cancer Res. 1998 Feb 1;58(3):437-41
pubmed: 9458086
Curr Treat Options Oncol. 2004 Dec;5(6):499-509
pubmed: 15509483
Nat Rev Clin Oncol. 2017 Jun;14(6):347-364
pubmed: 28094261
J Neuropathol Exp Neurol. 2017 Apr 1;76(4):289-298
pubmed: 28340171
Bioconjug Chem. 2007 Jul-Aug;18(4):1110-7
pubmed: 17503761
EJNMMI Res. 2016 Dec;6(1):6
pubmed: 26791386
J Neurooncol. 2007 Jan;81(2):167-74
pubmed: 16850106
Chembiochem. 2011 Mar 21;12(5):750-60
pubmed: 21328514
Mol Imaging Biol. 2010 Dec;12(6):583-94
pubmed: 20376568
PLoS One. 2017 Jul 21;12(7):e0181473
pubmed: 28732021
BMC Cancer. 2016 Nov 14;16(1):884
pubmed: 27842504
Int J Cancer. 2002 Apr 20;98(6):930-7
pubmed: 11948475
Int J Clin Exp Pathol. 2015 Oct 01;8(10):13185-92
pubmed: 26722517
Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1346-51
pubmed: 16847654
J Nucl Med. 2011 Nov;52(11):1778-85
pubmed: 21990576
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
J Nucl Med. 2016 Aug;57(8):1289-95
pubmed: 27127222
PLoS One. 2009 Nov 30;4(11):e8051
pubmed: 19956682